Hypera S.A. (HYPMY) Q2 2026 Earnings Call Transcript
Hypera S.A. (HYPMY) Q2 2026 Earnings Call Transcript
Hypera S.A. (HYPMY) Q4 2024 Earnings Call Transcript
Hypera S.A. (OTCPK:HYPMY) Q4 2023 Earnings Conference Call March 21, 2025 10:00 AM ET Company Participants Breno Toledo Pires de Oliveira - Chief Executive Officer Adalmario Ghovatto Satheler do Couto - Investor Relations Officer Ramon Sanches Frutuoso Silva - Chief Financial Officer Conference Call Participants Joseph Giordano - JP Morgan Robert Ford - Bank of America Mauricio Cepeda - Morgan Stanley Vinicius Figueiredo - Itau BBA Samuel Alves - BTG Pactual Operator Good morning, ladies and gentlemen.
Hypera: Short-Term Pain For Long-Term Gain
Hypera is a top pharmaceutical company in Brazil, dominating the OTC market with a strong brand portfolio. Overleveraged acquisitions, Brazil's slowing pharma market, and high interest rates have caused a sharp drop in Hypera's stock over the past five years. The company launched a plan to boost cash flow via reduced receivables and inventory, aiming for long-term profitability but facing short-term earnings challenges.
